Antibiotic Treatment of Resistant Infections in Small Animals

Veterinary Clinics of North America - Small Animal Practice

Volumn 43, Issue 5, 2013, Pages 1091-1107

  Papich, Mark G ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Antibiotics; Infection; Resistance; Small animals

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CARBAPENEM; CARBENICILLIN; CEFALEXIN; CEFOVECIN; CEFPODOXIME; CEFTAZIDIME; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; DICLOXACILLIN; DOXYCYCLINE; ENROFLOXACIN; GENTAMICIN; LINEZOLID; MEROPENEM; MINOCYCLINE; ORBIFLOXACIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SIMPLICEF; TICARCILLIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ADVERSE OUTCOME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG USE; EAR INFECTION; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HUMAN; INFECTION RESISTANCE; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PROTEUS; PSEUDOMONAS; PSEUDOMONAS INFECTION; RECOMMENDED DRUG DOSE; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STRANGLES; URINARY TRACT INFECTION; WOUND INFECTION;

ANIMALIA; BACILLI (CLASS); BACTERIA (MICROORGANISMS); NEGIBACTERIA; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS PSEUDINTERMEDIUS;

EID: 84880937077     PISSN: 01955616     EISSN: 18781306     Source Type: Journal    
DOI: 10.1016/j.cvsm.2013.04.006     Document Type: Review

References (72)

1. Clinical Laboratory Standards Institute (CLSI) Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals 2008, Approved Standard, Clinical and Laboratory Standards Institute, Wayne (PA), CLSI document M31-A3. 3rd edition.
2. Oluoch A.O., Kim C.H., Weisiger R.M., et al. Nonenteric Escherichia coli isolates from dogs: 674 cases (1990-1998). JAm Vet Med Assoc 2001, 218:381-384.
3. Torres S.M., Diaz S.F., Nogueira S.A., et al. Frequency of urinary tract infection among dogs with pruritic disorders receiving long-term glucocorticoid treatment. JAm Vet Med Assoc 2005, 227:239-243.
4. Shaheen B.W., Boothe D.M., Oyarzabal O.A., et al. Antimicrobial resistance profiles and clonal relatedness of canine and feline Escherichia coli pathogens expressing multidrug resistance in the United States. JVet Intern Med 2010, 24:323-330.
5. Martin Barrasa J.L., Lupiola Gomez P., Gonzalez Lama Z., et al. Antibacterial susceptibility patterns of Pseudomonas strains isolated from chronic canine otitis externa. JVet Med B Infect Dis Vet Public Health 2000, 47:191-196.
6. Colombini S., Merchant R.S., Hosgood G. Microbial flora and antimicrobial susceptibility patterns from dogs with otitis media. Vet Dermatol 2000, 11:235-239.
7. Petersen A.D., Walker R.D., Bowman M.M., et al. Frequency of isolation and antimicrobial susceptibility patterns of Staphylococcus intermedius and Pseudomonas aeruginosa isolates from canine skin and ear samples over a 6 year period (1992-1997). JAm Anim Hosp Assoc 2002, 38:407-413.
8. Pinchbeck L.R., Cole L.K., Hillier A., et al. Pulsed-field gel electrophoresis patterns and antimicrobial susceptibility phenotypes for coagulase-positive staphylococcal isolates from pustules and carriage sites in dogs with superficial bacterial folliculitis. Am J Vet Res 2007, 68(5):535-542.
9. Lloyd D.H., Lamport A.I., Feeney C. Sensitivity to antibiotics amongst cutaneous andmucosal isolates of canine pathogenic staphylococci in the UK, 1980-1996. Vet Dermatol 1996, 7:171-175.
10. Bond R., Loeffler A. What's happened to Staphylococcus intermedius? Taxonomic revision and emergence of multi-drug resistance. JSmall Anim Pract 2012, 53:147-154.
11. Weese J.S., van Duijkeren E. Methicillin-resistant Staphylococcus aureus and Staphylococcus pseudintermedius in veterinary medicine. Vet Microbiol 2010, 140(3-4):418-429.
12. Weese J.S. Methicillin-resistant Staphylococcus aureus: an emerging pathogen in small animals. JAm Anim Hosp Assoc 2005, 41(3):150-157.
13. Gortel K., Campbell K.L., Kakoma I., et al. Methicillin resistance among staphylococci isolated from dogs. Am J Vet Res 1999, 60:1526-1530.
14. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005, 40:562-573.
15. Jones R.D., Kania S.A., Rohrbach B.W., et al. Prevalence of oxacillin- and multidrug-resistant staphylococci in clinical samples from dogs: 1,772 samples (2001-2005). JAm Vet Med Assoc 2007, 230(2):221-227.
16. Bemis D.A., Jones R.D., Hiatt L.E., et al. Comparison of tests to detect oxacillin resistance in Staphylococcus intermedius, Staphylococcus schleiferi, and Staphylococcus aureus isolates from canine hosts. JClin Microbiol 2006, 44(9):3374-3376.
17. Bemis D.A., Jones R.D., Frank L.A., et al. Evaluation of susceptibility test breakpoints used to predict mecA-mediated resistance in Staphylococcus pseudintermedius isolated from dogs. JVet Diagn Invest 2009, 21(1):53-58.
18. Sasaki T., Kikuchi K., Tanaka Y., et al. Reclassification of phenotypically identified Staphylococcus intermedius strains. JClin Microbiol 2007, 45:2770-2778.
19. Bannoehr J., Guardabassi L. Staphylococcus pseudintermedius in the dog: taxonomy, diagnostics, ecology, epidemiology and pathogenicity. Vet Dermatol 2012, 23:253-266.
20. Dancer S.J. The effect of antibiotics on methicillin-resistant Staphylococcus aureus. JAntimicrob Chemother 2008, 61:246-253.
21. Harbarth S., Samore M.H. Interventions to control MRSA: high time for time-series analysis?. JAntimicrob Chemother 2008, 62:431-433.
22. Paterson D.L. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004, 38(Suppl 4):S341-S345.
23. Prescott J.F., Hanna W.J., Reid-Smith R., et al. Antimicrobial drug use and resistance in dogs. Can Vet J 2002, 43:107-116.
24. Bartlett J.G. Intra-abdominal sepsis. Med Clin North Am 1995, 79(3):599-617.
25. Papich M.G. Handbook of antimicrobial therapy for small animals 2011, Elsevier-Saunders, St Louis (MO), p. 140.
26. Papich M.G. Saunders handbook of veterinary drugs 2011, Elsevier-Saunders, St Louis (MO), p. 858. 3rd edition.
27. Papich M.G. Selection of antibiotics for methicillin-resistant Staphylococcus pseudintermedius: time to revisit some old drugs?. Vet Dermatol 2012, 23(4):352-360.
28. Papich M.G., Davis J.L., Floerchinger A.M. Pharmacokinetics, protein binding, and tissue distribution of orally administered cefpodoxime proxetil and cephalexin in dogs. Am J Vet Res 2010, 71(12):1484-1491.
29. Available at: Accessed May 26, 2013. http://www.eucast.org/mic_distributions/.
30. Stegemann M.R., Sherington J., Blanchflower S. Pharmacokinetics and pharmacodynamics of cefovecin in dogs. JVet Pharmacol Ther 2006, 29(6):501-511. PMID: 17083454.
31. Stegemann M.R., Sherington J., Coati N., et al. Pharmacokinetics of cefovecin in cats. JVet Pharmacol Ther 2006, 29(6):513-524. PMID: 17083455.
32. Stegemann M.R., Passmore C.A., Sherington J., et al. Antimicrobial activity and spectrum of cefovecin, a new extended-spectrum cephalosporin, against pathogens collected from dogs and cats in Europe and North America. Antimicrob Agents Chemother 2006, 50(7):2286-2292. PMID: 16801403.
33. Stegemann M.R., Coati N., Passmore C.A., et al. Clinical efficacy and safety of cefovecin in the treatment of canine pyoderma and wound infections. JSmall Anim Pract 2007, 48(7):378-386. PMID: 17559523.
34. Stegemann M.R., Sherington J., Passmore C. The efficacy and safety of cefovecin in the treatment of feline abscesses and infected wounds. JSmall Anim Pract 2007, 48(12):683-689. PMID: 17725587.
35. Passmore C.A., Sherington J., Stegemann M.R. Efficacy and safety of cefovecin (Convenia) for the treatment of urinary tract infections in dogs. JSmall Anim Pract 2007, 48(3):139-144. PMID: 17355604.
36. Six R., Cherni J., Chesebrough R., et al. Efficacy and safety of cefovecin in treating bacterial folliculitis, abscesses, or infected wounds in dogs. JAm Vet Med Assoc 2008, 233(3):433-439.
37. Livermore D.M. Of Pseudomonas, porins, pumps, and carbapenems. JAntimicrob Chemother 2001, 47:247-250.
38. Bidgood T., Papich M.G. Plasma pharmacokinetics and tissue fluid concentrations of meropenem after intravenous and subcutaneous administration in dogs. Am J Vet Res 2002, 63(12):1622-1628.
39. Papich M.G., Riviere J.E. Chapter 38. Fluoroquinolone antimicrobial drugs. Veterinary pharmacology and therapeutics 2009, 1524. Wiley-Blackwell Publishing, Ames (IA). 9th edition. J.E. Riviere, M.G. Papich (Eds.).
40. Boothe D.M., Debavalya N. Impact of routine antimicrobial therapy on canine fecal Escherichia coli antimicrobial resistance: a pilot study. Int J Appl Res Vet Med 2011, 9(4):396-406.
41. Riddle C., Lemons C., Papich M.G., et al. Evaluation of ciprofloxacin as a representative of veterinary fluoroquinolones in susceptibility testing. JClin Microbiol 2000, 38:1636-1637.
42. Rubin J., Walker R.D., Blickenstaff K., et al. Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections. Vet Microbiol 2008, 131(1-2):164-172.
43. Papich M.G. Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs. Am J Vet Res 2012, 73(7):1085-1091.
44. Albarellos G.A., Kreil V.E., Landoni M.F. Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats. JVet Pharmacol Ther 2004, 27:155-162.
45. Papich M.G., Riviere J.E. Chapter 36. Aminoglycoside antibiotics. Veterinary pharmacology and therapeutics 2009, 1524. Wiley-Blackwell Publishing, Ames (IA). 9th edition. J.E. Riviere, M.G. Papich (Eds.).
46. Konig C., Simmen H.P., Blaser J. Bacterial concentrations in pus and infected peritoneal fluid - implication of bactericidal activity of antibiotics. JAntimicrob Chemother 1998, 42:227-232.
47. Perreten V., Kadlec K., Schwarz S., et al. Clonal spread of methicillin-resistant Staphylococcus pseudintermedius in Europe and North America: an international multicentre study. JAntimicrob Chemother 2010, 65:1137-1144.
48. Ihrke P.J., Papich M.G., DeManuelle T.C. The use of fluoroquinolones in veterinary dermatology. Vet Dermatol 1999, 10:193-204.
49. Campbell K.L. Sulphonamides: updates on use in veterinary medicine. Vet Dermatol 1999, 10:205-215.
50. Noli C., Boothe D. Macrolides and lincosamides. Vet Dermatol 1999, 10:217-223.
51. Kadlec K., van Duijkeren E., Wagenaar J.A., et al. Molecular basis of rifampicin resistance in methicillin-resistant Staphylococcus pseudintermedius isolates from dogs. JAntimicrob Chemother 2011, 66:1236-1242.
52. Sentürk S., Özel E., Sen A. Clinical efficacy of rifampicin for treatment of canine pyoderma. Acta Vet Brno 2005, 74:117-122.
53. Falagas M.E., Bliziotis I.A., Fragoulis K.N. Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. Am J Infect Control 2007, 35(2):106-114.
54. Lobo M.C., Mandell G.L. Treatment of experimental staphylococcal infection with rifampin. Antimicrob Agents Chemother 1972, 2(3):195-200.
55. Reitman M.L., Chu X., Cai S., et al. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther 2011, 89(2):234-242.
56. Lee K.H., Shin J.G., Chong W.S., et al. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. Eur J Clin Pharmacol 1993, 45(3):287-289.
57. Papich M.G., Davidson G.S., Fortier L.A. Doxycycline concentration over time after storage in a compounded preparation for animals. J Am Vet Med Assoc 2013, in press.
58. Weese J.S., Sweetman K., Edson H., et al. Evaluation of minocycline susceptibility of methicillin-resistant Staphylococcus pseudintermedius. Vet Microbiol 2013, 162(2-4):968-971.
59. Barza M., Brown R.B., Shanks C., et al. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob Agents Chemother 1975, 8(6):713-720.
60. Wilson R.C., Kitzman J.V., Kemp D.T., et al. Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. Am J Vet Res 1985, 46(6):1316-1318.
61. Noble J.F., Kanegis L.A., Hallesy D.W. Short-term toxicity and observations on certain aspects of the pharmacology of a unique tetracycline-minocycline. Toxicol Appl Pharmacol 1967, 11(1):128-149.
62. Clark C.H. Chloramphenicol dosage. Mod Vet Pract 1978, 59(1):749-754.
63. Aidasani D., Zaya M.J., Malpas P.B., et al. Invitro drug-drug interaction screens for canine veterinary medicines: evaluation of cytochrome P450 reversible inhibition. Drug Metab Dispos 2008, 36:1512-1518.
64. Kukanich B., Kukanich K.S., Rodriguez J.R. The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. Vet Anaesth Analg 2011, 38(3):224-230.
65. Akesson C.E., Linero P.E. Effect of chloramphenicol on serum salicylate concentrations in dogs and cats. Am J Vet Res 1982, 43:1471-1472.
66. Sanders J.E., Yeary R.A., Fenner W.R., et al. Interaction of phenytoin with chloramphenicol or pentobarbital in the dog. JAm Vet Med Assoc 1979, 175(2):177-180.
67. Adams H.R., Dixit B.N. Prolongation of pentobarbital anesthesia by chloramphenicol in dogs and cats. JAm Vet Med Assoc 1970, 156(7):902-905.
68. Drusano G.L., Ambrose P.G., Bhavnani S.M., et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007, 45:753-760.
69. Vandecasteele S.J., De Vriese A.S., Tacconelli E. The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. JAntimicrob Chemother 2013, 68:743-748.
70. Gu B., Kelesidis T., Tsiodras S., et al. The emerging problem of linezolid-resistant Staphylococcus. JAntimicrob Chemother 2013, 68(1):4-11.
71. Slatter J.G., Adams L.A., Bush E.C., et al. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 2002, 32(10):907-924.
72. Bhamidipati R.K., Dravid P.V., Mullangi R., et al. Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones. Xenobiotica 2004, 36(6):571-579.